Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 28, 2014, Pages 10329-10334

  Stöhr, Jan ^a,b   Condello, Carlo ^a   Watts, Joel C ^a,b,c   Bloch, Lillian ^a   Oehler, Abby ^b   Nick, Mimi ^a   DeArmond, Stephen J ^a,b   Giles, Kurt ^a,b   DeGrado, William F ^a   Prusiner, Stanley B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; In vitro; Neurodegenerative diseases

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; DODECYL SULFATE SODIUM; PRION PROTEIN; PROTEINASE;

ADDITION REACTION; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BIOLUMINESCENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; IN VITRO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN POLYMERIZATION;

ALZHEIMER'S DISEASE; IN VITRO; NEURODEGENERATIVE DISEASES;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; HUMANS; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRIONS; TIME FACTORS;

EID: 84904333974     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408968111     Document Type: Article

References (42)

1. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol 124(3):305-323.
2. Prusiner SB (2012) Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336(6088):1511-1513.
3. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8(8):423-434.
4. Goudsmit J, et al. (1980) Evidence for and against the transmissibility of Alzheimer disease. Neurology 30(9):945-950. (Pubitemid 10059245)
5. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113(9):1243-1251. (Pubitemid 44291018)
6. Meyer-Luehmann M, et al. (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313(5794):1781-1784. (Pubitemid 44454153)
7. Mullan M, et al. (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1(5):345-347.
8. Sturchler-Pierrat C, et al. (1997) Two amyloid precursor protein transgenic mousemodels with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94(24):13287-13292. (Pubitemid 27518514)
9. Eisele YS, et al. (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330(6006):980-982.
10. Watts JC, et al. (2011) Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 108(6):2528-2533.
11. Stöhr J, et al. (2012) Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci USA 109(27):11025-11030.
12. Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic Aβ in different aggregation states. Methods Mol Biol 670:13-32.
13. Scott M, et al. (1989) Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59(5):847-857. (Pubitemid 20022375)
14. Sturchler-Pierrat C, Staufenbiel M (2000) Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 920:134-139. (Pubitemid 32056562)
15. 40 ratios in Alzheimer disease. J Biol Chem 287(8):5650-5660.
16. Prusiner SB, et al. (1990) Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63(4):673-686. (Pubitemid 120035041)
17. Bruce ME (1993) Scrapie strain variation and mutation. Br Med Bull 49(4):822-838.
18. Prusiner SB (1991) Molecular biology of prion diseases. Science 252(5012):1515-1522.
19. Bessen RA, Marsh RF (1994) Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 68(12):7859-7868. (Pubitemid 24362673)
20. Telling GC, et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274(5295):2079-2082. (Pubitemid 27020700)
21. Ayers JI, et al. (2011) The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog 7(3):e1001317.
22. Wickner RB (1994) [URE3] as an altered URE2 protein: Evidence for a prion analog in Saccharomyces cerevisiae. Science 264(5158):566-569.
23. Tanaka M, Collins SR, Toyama BH, Weissman JS (2006) The physical basis of how prion conformations determine strain phenotypes. Nature 442(7102):585-589. (Pubitemid 44167919)
24. Colby DW, et al. (2009) Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci USA 106(48):20417-20422.
25. Owen F, Poulter M, Collinge J, Crow TJ (1990) Codon 129 changes in the prion protein gene in Caucasians. Am J Hum Genet 46(6):1215-1216. (Pubitemid 20174705)
26. Parchi P, et al. (2010) Agent strain variation in human prion disease: Insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 133(10):3030-3042.
27. Carlson GA, et al. (1986) Linkage of prion protein and scrapie incubation time genes. Cell 46(4):503-511. (Pubitemid 16022406)
28. Westaway D, et al. (1987) Distinct prion proteins in short and long scrapie incubation period mice. Cell 51(4):651-662.
29. Heilbronner G, et al. (2013) Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice. EMBO Rep 14(11):1017-1022.
30. Jansen K, et al. (2001) Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form. Biol Chem 382(4):683-691. (Pubitemid 32472179)
31. Xiong L-W, Raymond LD, Hayes SF, Raymond GJ, Caughey B (2001) Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem 79(3):669-678. (Pubitemid 33029940)
32. Stöhr J, et al. (2008) Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA 105(7):2409-2414. (Pubitemid 351520527)
33. Rangachari V, et al. (2007) Amyloid-β(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry 46(43):12451-12462. (Pubitemid 350027406)
34. Barghorn S, et al. (2005) Globular amyloid β-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95(3):834-847. (Pubitemid 41567174)
35. Abelein A, et al. (2013) Formation of dynamic soluble surfactant-induced amyloid β peptide aggregation intermediates. J Biol Chem 288(32):23518- 23528.
36. Lu JX, et al. (2013) Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154(6):1257-1268.
37. Watts JC, et al. (2014) Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci USA 111:10323-10328.
38. Portelius E, et al. (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 120(2):185-193.
39. Moro ML, et al. (2012) APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38. Acta Neuropathol 124(6):809-821.
40. Ghaemmaghami S, et al. (2009) Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 5(11):e1000673.
41. Berry DB, et al. (2013) Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA 110(44):E4160-E4169.
42. Oelschlegel AM, Weissmann C (2013) Acquisition of drug resistance and dependence by prions. PLoS Pathog 9(2):e1003158.